semaglutide cv benefit 🧿 Oral is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending cardiovascular protection beyond injectable formulations. SOUL Trial: Oral Semaglutide & Cardiovascular Outcomes in T2DM In patients with cardiometabolic #HFpEF,

If you want to see what hitting those numbers looks like day to day, you can s ee what people said after following it for a week

Slowing food digestion in the stomach

The impact of xanthine oxidase (XO) on hemolytic diseases

They note it's a stable, oxidized compound and scientific research has failed to establish links to health issues

Diabetes Obes Metab 15(1):1527 Nauck MA, DAlessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Participants are encouraged to keep a symptom diary and report any new or worsening symptoms between visits